

Regeneron and Telix Pharmaceuticals just struck a deal worth up to $4.3 billion to co-develop radioligand cancer therapies. It's one of the largest radiopharma alliances ever, and it confirms that every major oncology player now wants nuclear-powered cancer drugs in their arsenal.
For years, Regeneron watched from the sidelines while Novartis, Eli Lilly, Bristol Myers Squibb, and AstraZeneca spent billions snapping up radiopharmaceutical companies like they were going out of style. Now, with a single partnership, Regeneron just crashed the party.
The antibody giant struck a deal with Australia's Telix Pharmaceuticals worth up to $4.3 billion to co-develop radioligand therapies for solid tumors. It's one of the largest radiopharmaceutical alliances ever. And it signals something bigger: the companies that built empires on antibodies now believe the future of cancer treatment involves strapping radioactive atoms to those same molecules.
Radioligand therapy works like a guided missile. You take a molecule that locks onto cancer cells, attach a radioactive payload, and inject it into the bloodstream. The molecule finds the tumor. The radiation kills it. Healthy tissue mostly gets spared.
Novartis proved this could be a blockbuster business. Its radioligand drug Pluvicto, which targets prostate cancer, generated nearly $980 million in sales in 2023 alone. That single product turned an entire modality from "interesting academic concept" into "must-have for every pharma portfolio."
Since then, the dealmaking has been relentless. BMS bought RayzeBio for $4.1 billion. Lilly grabbed Point Biopharma for $1.4 billion. AstraZeneca acquired Fusion Pharmaceuticals for up to $2.4 billion. The radioligand therapy market, currently worth roughly $2.6 to $3.0 billion, is projected to grow at double-digit rates through the end of the decade.
Regeneron, whose oncology strategy has been almost entirely antibody-based, was conspicuously absent from this land grab. Until now.
Let's be clear: Regeneron is not writing a $4.3 billion check. That number is the theoretical maximum if everything goes perfectly across up to eight programs. Think of it like a real estate deal where you put down earnest money and agree to pay more if the house appraises well, the inspection clears, and the neighborhood turns into the next Brooklyn.

FDA staff are raising alarms about who actually has the authority to approve drugs under the Priority Review Voucher system. With vouchers now selling for up to $200 million and billions in rare disease investment hanging in the balance, the confusion couldn't come at a worse time.


Join thousands of biotech professionals who start their day with our free, daily briefing.
The actual upfront payment? $40 million from Regeneron to Telix for access to the first four therapeutic programs. That's a rounding error on Regeneron's balance sheet.
The structure gets interesting from there. For each program, the two companies will split development costs and profits 50/50 by default. But Telix has an escape hatch: it can opt out of co-funding any individual program. If it does, Telix instead collects up to $535 million in milestones per program, plus royalties in the low double digits on net sales.
Regeneron can also expand the partnership by adding up to four more programs beyond the initial four. If it exercises all those options and every milestone is hit across all eight programs, you get to that $4.3 billion headline. In practice, the chances of every milestone firing across every program are about as likely as a perfect March Madness bracket. But even partial success here could be enormous.
There's a diagnostics component too. Telix will lead commercialization of any companion radiodiagnostic agents (think: imaging tools that find the tumors before the therapy kills them), with Regeneron taking a cut of the profits.
Regeneron brings one of the deepest antibody toolboxes in the industry. Its VelocImmune platform can generate fully human antibodies at scale, including bispecific antibodies that grab two different targets at once. What Regeneron doesn't have is any experience turning those antibodies into radioactive cancer killers.
Telix fills that gap. The Australian company has built a specialty in radiopharmaceutical manufacturing, radiolabeling chemistry, and the regulatory know-how needed to get radioactive drugs through approval. Its lead commercial product, Illuccix (a PSMA-targeted PET imaging agent for prostate cancer), is already approved in the U.S., Europe, Australia, and Canada.
So the logic is straightforward: Regeneron picks the targets and designs the antibodies. Telix attaches the radioactive warheads and handles the uniquely complex manufacturing. Both companies share the rewards.
Wall Street analysts at Truist described the alliance as Regeneron's "entry ticket" to radiopharma, noting it adds a new therapeutic modality to a pipeline that had been exclusively focused on conventional antibodies and checkpoint inhibitors.
Step back and look at the scoreboard. In just the last two years, big pharma has collectively spent more than $10 billion acquiring or partnering with radiopharmaceutical companies. Novartis, BMS, Lilly, AstraZeneca, and now Regeneron have all placed major bets.
That's not a trend. That's a consensus.
The radioligand therapy market is still young, worth only a few billion dollars today. But the growth trajectory is steep. The key catalysts include more product approvals, expansion into new cancer types beyond prostate, and the buildout of manufacturing infrastructure for radioactive drugs (which is genuinely hard; you can't exactly stockpile materials with a half-life measured in days).
For specialist radiopharma companies, this creates a fascinating dynamic. Every major deal increases the perceived value of the remaining independent players. If you're a mid-cap company with radioligand manufacturing expertise and a decent pipeline, your phone is probably ringing.
Plenty. The $4.3 billion headline is built on programs that are still early-stage, meaning years of clinical development, regulatory hurdles, and competitive pressure stand between today and any meaningful revenue.
For Telix specifically, the 50/50 cost-sharing model means higher R&D spending for the foreseeable future. That's a tough sell in a market where investors have been rewarding biotech companies that demonstrate fiscal discipline and a path to profitability. Telix also faces a major binary event in September 2026: the FDA decision on Pixclara, its brain cancer imaging agent. A rejection there could reignite concerns about the company's near-term financial footing, even with the Regeneron deal in hand.
For Regeneron, the risk is different. Radiopharma manufacturing is a completely different beast from producing monoclonal antibodies. Supply chains for medical isotopes are fragile and geographically concentrated. Regeneron is leaning on Telix's expertise here, but scaling that expertise across eight programs simultaneously is no small feat.
And then there's competition. Novartis has a multi-year head start with two approved products and a growing pipeline. Lilly, BMS, and AstraZeneca are all racing to get their own radioligand drugs to market. The PSMA target in prostate cancer is getting particularly crowded.
Regeneron joining the radiopharma wave isn't just another deal announcement. It's a signal that antibody-based radioligand therapies (where you use an antibody, not a small molecule, to deliver radiation) could become the next frontier in precision oncology.
The partnership validates Telix as more than a niche imaging company. It validates radioligand therapy as a modality that every major oncology player now feels compelled to own. And it raises the stakes for the shrinking pool of independent radiopharma companies that haven't yet been acquired or partnered.
The nuclear age of cancer treatment isn't coming. It's here. And Regeneron just made sure it has a seat at the table.
Eli Lilly dropped $202 million on a startup with zero human data and a technology that could make viral gene therapy delivery obsolete. The bet makes more sense than you'd think.